1717 K Street NW, Suite 900

Washington, DC 20006-5349

(877) 363-6376

HELPLINE

NEWS

A letter from a mesothelioma surgeon about treatment during Covid-19

treatment during covid-19

Below, Dr. Taylor Ripley, a thoracic surgeon at Baylor and a member of the board of directors of the Mesothelioma Applied Research Foundation, takes a moment to discuss challenges in mesothelioma treatment introduced by Covid-19. Specifically, he would like to encourage patients experiencing symptoms, and those who have missed scans, to seek a consultation with their physicians rather than to wait for Covid-19 to pass. Patients may also find it useful to read through these Covid-19 guidelines specific to mesothelioma patients written by our experts.

By R. Taylor Ripley, MD

We are now at 6 months of this pandemic in the United States – at least since we recognized it. In mid-March in Houston, TX, a few patients and I debated whether to proceed with surgery for malignant pleural mesothelioma (MPM) or to delay as the ‘peak’ passed. At that time, we shut down elective procedures, reduced visits to urgent and emergent only, and limited public gatherings. We improved telemedicine and virtual visits and instituted safety protocols in the hospitals. We did not experience a peak in April or May. We hoped, incorrectly, that our area avoided the extent of the tragedies that occurred in other cities such as New York. Due to significant risk of progression of MPM as well as other cancers such as lung and esophageal cancer, we continued to operate as necessary during the initial shut down.

Fortunately, we did not delay those operations. This pandemic did not rise and fall in one month. In our city, operating in June would be no safer than April. In July, our community in Houston and in Texas experienced peaks in both the numbers of patients with disease and, importantly, with critical illness requiring intensive care support. While this timing is specific for Texas, the pattern is not different from much of the United States given that Covid-19 continues to claim thousands of lives.

Managing patient care

Most of the patients with MPM whom we have managed during this crisis have had an established diagnosis. Our patients with MPM and lung cancer often are older and have lung disease such as COPD and emphysema. The risk of severe illness with Covid-19 is much greater with this group of patients compared to the general population. Many of our patients have remained quarantined now for six months. Telemedicine has kept us in contact with our established patients while limiting travel outside of their home. Telemedicine may help our established patients, however, the continued quarantine may prevent patients from seeking care who were not diagnosed prior to the pandemic.

In June, Dr. Norman E. Sharpless, Director of the U.S. National Cancer Institute, warned that consequences for avoiding screening, diagnosis, and treatment of non-Covid-19 disease will likely results in excessive cancer deaths over the next several years (https://science.sciencemag.org/content/368/6497/1290). He stated that for cancers that are missed now at a potentially early stage, eventually will appear and likely be a higher stage. At least anecdotally, we are seeing few numbers of patients with new diagnosis of MPM who are minimally symptomatic. Many of our patients are symptomatic with shortness of breath and chest pain. We may look back and note that more patients had higher staged disease during this period. Unfortunately, observing these differences after the fact will not help our patients at this time. So, what can we do now?

When should mesothelioma patients seek treatment during Covid-19?

Symptoms for MPM and lung cancer are often associated with advanced disease. For patients experiencing increased shortness of breath, chest pain, persistent cough, swelling in extremities, or any other new symptom, I would strongly recommend seeing your physician and not waiting for Covid-19 to pass. Now that we are six months into this pandemic without a clear end in sight, seeking care for screening and diagnosis is as important as ever. Significant progression of MPM often occurs over six months. While clinics have improved safety protocols, patients can reduce the risk by wearing a mask, washing hands, and distancing of at least six feet when visiting their physicians. Ignoring symptoms and avoiding screening is not a safety protocol.

We all remain committed to care for patients with disease other than Covid-19. Please reach out to your physician for missed screening and new symptoms.

R. Taylor Ripley, MD, Director, Mesothelioma Treatment Center Associate Professor of General Thoracic Surgery
Baylor College of Medicine

Also...

In Other News

Share:

Facebook
Twitter
LinkedIn